drugset / Trial / NCT04166721
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with advanced unresectable or metastatic OGA who have progressed following chemotherapy.
Timeline
- Start
- 2020-02-11
- Primary completion
- 2025-03-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | Intravenous |
| Subject | DKN-01 | Monoclonal antibody | 150 mg | Intravenous |
| Subject | DKN-01 | Monoclonal antibody | 300 mg | Intravenous |
| Subject | DKN-01 | Monoclonal antibody | 600 mg | Intravenous |